VERQUVO has been extensively and specifically evaluated in the VICTORIA study, demonstrating powerful efficacy in chronic heart failure (HF) patients following a worsening HF event.1
VICTORIA is the first positive outcome Phase III clinical study to focus exclusively on patients with chronic heart failure (HF) following a worsening HF event.1
- VERQUVO delivers a superior annual ARR of 4.2% for cardiovascular (CV) death and HF hospitalization combined, compared to background therapies alone.
- The number needed to treat (NNT) with VERQUVO for one year to prevent a primary outcome event is approximately 24.
The VICTORIA study involved 5,050 patients with chronic HF in 600 centers, in 42 countries, across the globe.1
Improve your patients’ chances of staying alive and out of hospital following a worsening HF event by adopting a therapy that will significantly reduce their risk of another event.
The VICTORIA study is different from other contemporary HF studies
In the VICTORIA study, VERQUVO was investigated in a patient population that had been insufficiently studied in other contemporary HF trials.1
- 90% of patients were already on at least 2 guideline-based HF therapies.
- 60% received triple therapy, including ACEI/ARNIs, ARBs, beta blockers and MRAs.
The primary outcome was a composite of death from CV causes or first hospitalization for HF.1
The VICTORIA study shows that VERQUVO, when added to background therapies, can reduce the combined risk of CV death and HF hospitalization following a worsening HF event.1
Reference list:
- Armstrong, PW et al. Vericiguat in patients with heart failure and reduced ejection fraction. N Engl J Med. 2020; 382:1883-1893. Return to content
- McMurray JJV et al. Dapagliflozin in patients with heart failure and reduced ejection fraction. N Engl J Med. 2019; 381:1995–2008 Return to content
- McMurray JJV et al. The dapagliflozin and prevention of adverse outcomes in heart failure (DAPA-HF) trial: baseline characteristics. Eur J Heart Fail. 2019; 21:1402–1411. Return to content
- Zile MR et al Prognostic implications of changes in n-terminal pro-b-type natriuretic peptide in patients with heart failure. J Am Coll Cardiol. 2016; 68:2425–2436. Return to content
- Solomon SD et al. Efficacy of sacubitril/valsartan relative to a prior decompensation: The PARADIGM-HF trial. JACC Heart Fail. 2016; 4:816–822. Return to content
- McMurray JJ et al. Angiotensin-neprilysin inhibition versus enalapril in heart failure. N Engl J Med. 2014; 371:993–1004. Return to content
- Pieske B et al. Baseline features of the VICTORIA trial. Eur J Heart Fail. 2019; 21:1596–1604. Return to content
© Bayer AG 2021
This web page contains information on Verquvo which is based on the Summary of Product Characteristics (SPC) as approved by the European Commission. It is intended to provide information to an international audience outside the US and UK.
- PP-VER-ALL-0172-2
